newsfilter
← Latest News
GlobeNewswire·

Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update

ANAB
  • Jemperli global net sales reached $1.0 billion (£753 million) for the nine months ended September 30, 2026, reflecting 29% year-over-year growth.
  • The U.S. FDA approved Jemperli as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer in October 2026.
  • GSK reported Jemperli global net sales of $365 million (£273 million) for the three months ended September 30, 2026, representing 20% year-over-year growth.
  • Anaptys receives royalties equal to 12% of Jemperli net sales between $1.0 billion and $1.5 billion in a calendar year.
  • Anaptys expects to achieve over $390 million in annualized Jemperli royalties payable by 2029 based on GSK's peak sales guidance.
  • Sagard is estimated to have accrued approximately $330 million in royalties and milestones through September 30, 2026, with remaining debt paydown anticipated in H2 2027.
  • Regulatory submissions for Jemperli are expected in Japan in H1 2027, with Europe and China submissions in H2 2027.
  • AZUR-2 (colon cancer) and JADE (head and neck cancer) pivotal trial data are expected in 2028, while AZUR-4 Phase 2 completion is due in Q4 2026.
  • The FDA target action date (PDUFA) for Vanda's Quimilza in generalized pustular psoriasis is December 12, 2026.
  • A post-trial hearing in the GSK and Tesaro litigation occurred on October 20, 2026, with a judgment anticipated in Q4 2026 or Q1 2027.
  • Anaptys reported collaboration revenue of $30.3 million for the three months ended September 30, 2026, a decrease from $76.3 million in the same period in 2025.
  • General and administrative expenses were $11.6 million for the quarter ended September 30, 2026, driven primarily by legal costs for the GSK and Tesaro lawsuit.
  • Net income from continuing operations was $3.9 million ($0.13 per share) for the three months ended September 30, 2026.
  • Cash, cash equivalents, and investments totaled $153.0 million as of September 30, 2026, down from $164.1 million as of June 30, 2026.
Company
AnaptysBio, Inc.
Keywords
Nasdaq:ANAB, AnaptysBio, Inc.